Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
Epithalon vs. Cagrilintide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both are included in the Relay research library, but their current records answer substantially different questions.
⇄ Different
Biggest Difference
Epithalon is distinguished by a synthetic four-amino-acid AEDG peptide, distinct from Epithalamin bovine pineal extract. Its evidence base is dominated by cell and animal studies rather than controlled human outcomes; Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
Epithalon is distinguished in the current record by a synthetic four-amino-acid AEDG peptide, distinct from Epithalamin bovine pineal extract. Its evidence base is dominated by cell and animal studies rather than controlled human outcomes. Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceCagrilintide
Epithalon: Preclinical evidence. Cagrilintide: Developing human evidence.
Regulatory historyComparable
Epithalon: Not FDA approved. Cagrilintide: Investigational — Phase 3.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
Epithalon
- Telomere and telomerase biology
- Circadian and melatonin biomarkers
- Lifespan in flies and rodents
- Oxidative stress and antioxidant pathways
Cagrilintide
- Weight management
- Appetite and energy intake
- Obesity with type 2 diabetes
- Visceral and ectopic fat
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
EpithalonNot FDA approved
Not FDA approved. FDA lists Epitalon among compounded bulk substances that may present significant safety risks and says route-specific human safety information is insufficient.
CagrilintideInvestigational
Investigational. No FDA-approved standalone cagrilintide product, consumer dose, reconstitution method, or official storage procedure.
Evidence depthEvidence, not a winner
EpithalonMostly cell + animal
One limited human circadian-biomarker report, multiple cultured-cell experiments, and fly and rodent studies. No robust controlled human anti-aging or lifespan trial was located.
CagrilintidePhase 2 + Phase 3 pending
One published 706-participant Phase 2 monotherapy trial, a 105-participant thorough-QT study, sponsor-reported Phase 3 component-arm data, and two active dedicated Phase 3 RENEW trials without posted results.
Weight outcomesEvidence, not a winner
EpithalonNot demonstrated
No dedicated controlled human weight-loss or body-composition evidence was located.
CagrilintidePeer-reviewed Phase 2
Phase 2 reported mean reductions of 6.0% to 10.8% across studied cagrilintide arms versus 3.0% placebo at 26 weeks. A sponsor-reported Phase 3 component arm later reported 11.8% versus 2.3% at 68 weeks under an efficacy estimand.
Type 2 diabetesEvidence, not a winner
EpithalonCell model only
A 2025 retinal-cell study used a high-glucose injury model. That is laboratory evidence, not diabetes or diabetic-retinopathy treatment evidence in patients.
CagrilintidePhase 3 registered
RENEW 2 is studying standalone cagrilintide in adults with overweight or obesity and type 2 diabetes; no results were posted by the cutoff.
Obstructive sleep apnoeaEvidence, not a winner
EpithalonNo dedicated evidence
No dedicated controlled obstructive-sleep-apnoea or clinical sleep-outcomes evidence was located.
CagrilintideNo dedicated evidence
No dedicated completed controlled human obstructive-sleep-apnoea outcome study was located.
Cardiovascular outcomesEvidence, not a winner
EpithalonNo outcomes evidence
No cardiovascular-outcomes or cardiovascular-benefit program was located.
CagrilintideQT study only
A 105-participant thorough-QT study found no clinically relevant QTc prolongation at the tested exposure. That narrow result is not a cardiovascular outcomes trial.
Administration and handlingEvidence, not a winner
EpithalonNo approved protocol
No approved human dose, route, schedule, cycle, or conversion exists. Cell concentrations and animal exposure schedules are research details only.
CagrilintideTrial descriptions only
Published and registered studies describe once-weekly subcutaneous administration under protocol-specific escalation. These are trial descriptions, not approved dosing instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Whether any laboratory or animal signal translates into meaningful human benefit and whether repeated human exposure is safe.
- Whether the dedicated RENEW Phase 3 trials confirm long-term standalone efficacy and safety in people with and without type 2 diabetes.
Community Intelligence
Emerging patterns, clearly separated from evidence
Epithalon
No community experiences yetBe the first account holder to contribute.
Cagrilintide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.